Loading
Life sciences · Journal article
Folia Medica · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction: Reliable peripheral immune biomarkers for monitoring response to anti-PD-1 therapy in metastatic NSCLC remain poorly defined. Dynamic changes within circulating T-cell compartments may reflect early pharmacodynamic immune remodeling associated with treatment response. Aim: To evaluate early peripheral T-cell immune dynamics during anti-PD-1 therapy and explore their potential as biomarkers of radiologic response. Materials and methods: Prospective paired peripheral blood immune profiling was performed in patients with metastatic NSCLC treated with pembrolizumab-based combination immunochemotherapy at baseline and after completion of four treatment cycles. Multicolor flow cytometry was used to assess T-cell activation (CD69), co-stimulatory competence (CD8⁺ CD28⁺), and regulatory T cells (Treg). Baseline-to-cycle-4 changes were analyzed descriptively and compared according to radiologic response. Results: Four patients with paired immune assessments were included. Two achieved partial response (PR) and two had stable disease (SD). Early peripheral immune remodeling was observed across patients, characterized by decreased CD4⁺ CD69⁺ and CD8⁺ CD69⁺ T cells and increased Treg frequencies. A consistent increase in CD8⁺ CD28⁺ T cells was observed in PR patients, whereas SD patients demonstrated heterogeneous changes. These findings suggest differential early modulation of CD8⁺ co-stimulatory capacity according to treatment response. Conclusions: Early peripheral T-cell immune dynamics during pembrolizumab-based immunochemotherapy may reflect biologically relevant immune remodeling associated with radiologic response. Serial flow-cytometric monitoring of CD8⁺ CD28⁺ T cells may represent a promising candidate peripheral biomarker and warrants further investigation in larger cohorts.